Opticyte

Join us during September as we focus on fighting the leading cause of death in US hospitals, during Sepsis Awareness Month. Together we can tackle this global threat. We’re sharing critical resources to help educate and advocate for change from the status quo from the Sepsis Alliance, the Global Sepsis Alliance and the Washington State Hospital Association to help educate others to recognize the signs and prevent infections that can lead to sepsis. Join Opticyte as we work fast to develop new technology to help clinicians recognize sepsis early and help save lives by empowering yourself and others through awareness to help stop sepsis. #SepsisAwarenessMonth #GetAheadOfSepsis #TogetherAgainstSepsis

Health equity champions, listen up and get ready to comment! The FDA's new discussion paper, "Health Equity For Medical Devices" is sparking conversations and helping build important momentum for change. We’re overdue to consider how we build clinical trial designs that prioritize diversity and inclusivity. Key points from the paper we’re reacting to: • How do demographics, socioeconomic status, and healthcare access impact disease prevalence and severity? • Are outcome disparities among patient populations device-related? • Could limited diversity in trials lead to the FDA requiring labeling that a device has demonstrated it is safe and effective for specific populations? These questions are crucial as we work towards more equitable medical devices like our VitalO₂ device. Take a deeper dive, you can find the full discussion paper and provide comments on the FDA's website. #HealthEquity #MedicalDevices #ClinicalTrials #Diversity

When a serious medical condition is recognized, it can be treated.  At Opticyte, our mission is to illuminate illness that is unseen. Sepsis is the leading cause of death in U.S. hospitals. It’s an unfortunate truth that you or someone you know has likely been impacted by sepsis. Early sepsis detection is one of the most critical unmet needs in medicine today. Pulse oximeters were developed nearly a half century ago, and they misdiagnose Black patients with dire conditions such as COVID-19, pneumonia, and COPD nearly 3x more often than White patients. Inaccuracies in today’s pulse oximeters result in delayed treatment and increased mortality rates.   At Opticyte, we are  harnessing our proprietary VitalO2 technology which is proven – in our latest study – to provide accurate readings to help quickly detect sepsis across different skin tones. Explore how you can join our journey and how Opticyte is stepping up to fight sepsis and improve health equity for hospital patients of color. 

Our CEO Lori Arakaki shares new research and her perspective on the urgent need for health equity in the pulse oximetry space. Discover how outdated technology has impacted patient outcomes, particularly in communities of color, and learn about the innovative solutions we are developing to address these disparities. Join us in our mission to create a healthier future for all. #HealthEquity #PulseOximetry #Innovation

As September approaches, we're gearing up for Sepsis Awareness Month. However, at Opticyte, our focus on detecting sepsis in people of all skin tones isn't limited to just one month - it's our mission every single day. Sepsis is a life-threatening condition affecting nearly 50 million people globally each year. Our dedicated team is working hard to develop an innovative solution that can help save lives across diverse populations. Our leading-edge technology aims to overcome the challenges in detecting sepsis early, which can be particularly difficult in individuals with darker skin tones. To see our progress and learn more about how we're planning to help tackle this global health crisis, check out our video. Don't forget to follow our page for updates as we continue to advance our mission of improving sepsis detection and treatment for everyone, everywhere. Together, we can make a difference in the fight against sepsis. #SepsisAwareness #HealthcareInnovation #MedTech  https://lnkd.in/gvZGGrp2

We're excited for Lori Arakaki to be a featured speaker at the Optica #MedTech Industry Summit this fall. It's an honor and fantastic opportunity to engage with other stakeholders for optics-based medical devices. Lori will be sharing details of our VitalO₂ monitor for noninvasive blood and cellular oxygenation measurement. Learn more about the conference here: https://lnkd.in/gxU3csuk

An observational study conducted by the University of Washington and Swedish has been using Opticyte’s VitalO₂ monitor to collect data during cardiac surgery and recovery. The study has now completed enrollment with data on 60 patients! 🌟   The study was designed to see if Cell O₂ can help predict and identify vasoplegia, a dangerous form of shock that can occur during or after cardio-pulmonary bypass.  A huge THANK YOU to all the study staff, clinical teams, and patient volunteers for their support of this research.  

We loved spending time at WEB | Health Tech with so many incredible founders like Lori Arakaki, co-founder and CEO at Opticyte. Opticyte is developing a noninvasive medical devise to monitor blood and cell oxygenation, with the advantage of eliminating bias due to skin tone.  

It was an impactful and truly enjoyable day that I spent with so many talented and accomplished women at Project W's WEB program for Health Tech. It is a difficult road that we female founders have chosen, and I can't thank Lynn Loacker, Amanda McFadden, and the DWT team enough for providing this opportunity to learn from and be supported by women who have paved the way.

We're honored to be featured by the National Heart, Lung, and Blood Institute in this new article about our VitalO₂ device. NHLBI's non-dilutive funding for Opticyte has been essential for the product development and research on Cell O₂'s clinical value. A huge thank you to NHLBI for the support! https://lnkd.in/g4YihsDa